RS67158B1 - 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti - Google Patents

1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti

Info

Publication number
RS67158B1
RS67158B1 RS20250853A RSP20250853A RS67158B1 RS 67158 B1 RS67158 B1 RS 67158B1 RS 20250853 A RS20250853 A RS 20250853A RS P20250853 A RSP20250853 A RS P20250853A RS 67158 B1 RS67158 B1 RS 67158B1
Authority
RS
Serbia
Prior art keywords
pyrazol
derivatives
methyl
treatment
neovascular diseases
Prior art date
Application number
RS20250853A
Other languages
English (en)
Inventor
Andrew Douglas Baxter
Jonathan Morris
Original Assignee
Exonate Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonate Ltd filed Critical Exonate Ltd
Publication of RS67158B1 publication Critical patent/RS67158B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20250853A 2020-07-14 2021-07-14 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti RS67158B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2010829.6A GB202010829D0 (en) 2020-07-14 2020-07-14 Compounds for treatment of neovascular diseases
PCT/GB2021/051810 WO2022013555A1 (en) 2020-07-14 2021-07-14 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases
EP21748927.7A EP4182311B1 (en) 2020-07-14 2021-07-14 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases

Publications (1)

Publication Number Publication Date
RS67158B1 true RS67158B1 (sr) 2025-09-30

Family

ID=72139988

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250853A RS67158B1 (sr) 2020-07-14 2021-07-14 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti

Country Status (23)

Country Link
US (2) US12024504B2 (sr)
EP (1) EP4182311B1 (sr)
JP (1) JP7827690B2 (sr)
KR (1) KR20230052890A (sr)
CN (1) CN116075506B (sr)
AU (1) AU2021309894A1 (sr)
BR (1) BR112023000571A2 (sr)
CA (1) CA3183466A1 (sr)
DK (1) DK4182311T3 (sr)
ES (1) ES3039003T3 (sr)
FI (1) FI4182311T3 (sr)
GB (1) GB202010829D0 (sr)
HR (1) HRP20250955T1 (sr)
HU (1) HUE072558T2 (sr)
LT (1) LT4182311T (sr)
MX (1) MX2023000570A (sr)
PL (1) PL4182311T3 (sr)
PT (1) PT4182311T (sr)
RS (1) RS67158B1 (sr)
SI (1) SI4182311T1 (sr)
SM (1) SMT202500307T1 (sr)
WO (1) WO2022013555A1 (sr)
ZA (1) ZA202301105B (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202010829D0 (en) * 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases
CN120917015A (zh) * 2023-01-20 2025-11-07 元启(苏州)生物制药有限公司 Srpk1抑制剂和使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US7569536B2 (en) 2003-12-26 2009-08-04 Masatoshi Hagiwara Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
GB0803912D0 (en) 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
JP2012509306A (ja) 2008-11-22 2012-04-19 ザ ユニバーシティ オブ ブリストル VEGFxxxbの新規な使用
GB201009173D0 (en) 2010-05-28 2010-07-14 Univ Bristol Treatment of pain
JP2016504270A (ja) 2012-10-17 2016-02-12 ザ ユニバーシティ オブ ブリストル 眼血管形成(ocularneovasculan)を治療するのに有用な化合物
GB201406956D0 (en) 2014-04-17 2014-06-04 Univ Nottingham Compounds
GB201518365D0 (en) 2015-10-16 2015-12-02 Exonate Ltd Compounds
PT3266446T (pt) * 2016-07-07 2019-01-30 Salvat Lab Sa Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média
WO2019063996A1 (en) 2017-09-27 2019-04-04 Exonate Limited INHIBITORS OF SRPK1
EP3691112B1 (en) 2017-09-29 2022-06-22 Hitachi Industrial Equipment Systems Co., Ltd. Data obtaining method, inverter, and rotating electric machine
GB202010829D0 (en) * 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases

Also Published As

Publication number Publication date
HRP20250955T1 (hr) 2025-10-10
FI4182311T3 (fi) 2025-08-22
MX2023000570A (es) 2023-04-19
JP2023535157A (ja) 2023-08-16
US12024504B2 (en) 2024-07-02
CA3183466A1 (en) 2022-01-20
AU2021309894A1 (en) 2023-03-09
GB202010829D0 (en) 2020-08-26
EP4182311B1 (en) 2025-06-04
JP7827690B2 (ja) 2026-03-10
DK4182311T3 (da) 2025-08-25
SI4182311T1 (sl) 2025-11-28
ES3039003T3 (en) 2025-10-16
CN116075506A (zh) 2023-05-05
US20240300929A1 (en) 2024-09-12
HUE072558T2 (hu) 2025-11-28
WO2022013555A1 (en) 2022-01-20
BR112023000571A2 (pt) 2023-01-31
EP4182311A1 (en) 2023-05-24
CN116075506B (zh) 2025-10-10
ZA202301105B (en) 2025-07-30
PT4182311T (pt) 2025-08-27
LT4182311T (lt) 2025-09-25
US20220411412A1 (en) 2022-12-29
PL4182311T3 (pl) 2025-11-12
KR20230052890A (ko) 2023-04-20
SMT202500307T1 (it) 2025-11-10

Similar Documents

Publication Publication Date Title
IL290415A (en) Compounds with deuterium for use in cancer treatment
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
SI4340842T1 (sl) Sotorasib za uporabo pri zdravljenju raka
PT4182311T (pt) Derivados de 1-metil-1h-pirazol-3-ilo para utilização no tratamento de doenças neovasculares
PL4419526T3 (pl) Związki heterocykliczne do stosowania w leczeniu nowotworu
IL321393A (en) CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
IL290427A (en) Objects and methods for administering medical agents
PL3937948T3 (pl) Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
GB202002299D0 (en) Agents for use in the treatment of tissue damage
GB202014589D0 (en) Agents for use in the treatment of amyloidosis
AU2023902805A0 (en) Combination for use in the treatment of glioma
HK40087864A (en) Methylthioninium compounds for use in the treatment of covid-19
HK40088920A (en) Methylthioninium compounds for use in the treatment of covid-19
CA3304484A1 (en) Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
HK40087155A (en) Composition for use in the treatment of apol1-associated disease
EP4346859A4 (en) USE OF A HISTEPIDULIN COMBINATION IN THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY
GB202414668D0 (en) Ultrasound-responsive nanoscale delivery platform for use in the treatment of biofilm-associated diseases
CA3267850A1 (en) USE OF BORATE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
GB202302121D0 (en) Compounds for use in the treatment of schizophrenia
CA3303478A1 (en) Polypeptides for use in the treatment of glypican-3-expressing tumours
HK40079284A (en) Agents for use in the treatment of tissue damage